Two trials were performed to evaluate the effect of renal and hepatic impairment on the pharmacokinetics of pritelivir and its metabolites. The renal impairment trial included subjects with mild, moderate, and severe impairment, while the hepatic impairment trial included subjects with moderate impairment. Both trials recruited a matched control group of healthy subjects.
View Article and Find Full Text PDFPritelivir is a novel viral helicase-primase inhibitor active against herpes simplex virus. In vitro drug-drug interaction studies indicated that pritelivir has the potential for clinically relevant interactions on the cytochrome P450 (CYP) enzymes 2C8, 2C9, 3A4, and 2B6, and intestinal uptake transporter organic anion transporting polypeptide (OATP) 2B1 and efflux transporter breast cancer resistance protein (BCRP). This was evaluated in 2 clinical trials.
View Article and Find Full Text PDFBackground: Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection is an uncommon problem typically seen in immunocompromised hosts. Systemic treatment options are limited. The performance of foscarnet and its toxicities in this population are poorly characterized.
View Article and Find Full Text PDFThe discovery that listeners more accurately identify words repeated in the same voice than in a different voice has had an enormous influence on models of representation and speech perception. Widely replicated in English, we understand little about whether and how this effect generalizes across languages. In a continuous recognition memory study with Hindi speakers and listeners (N = 178), we replicated the talker-specificity effect for accuracy-based measures (hit rate and D'), and found the latency advantage to be marginal (p = 0.
View Article and Find Full Text PDF